Dyne Therapeutics, Inc. (DYN)
| Market Cap | 3.39B +13.4% |
| Revenue (ttm) | n/a |
| Net Income | -604.92M |
| EPS | -3.66 |
| Shares Out | 187.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,359,190 |
| Open | 17.68 |
| Previous Close | 17.36 |
| Day's Range | 17.40 - 18.33 |
| 52-Week Range | 14.00 - 27.31 |
| Beta | 1.21 |
| Analysts | Strong Buy |
| Price Target | 34.33 (+89.98%) |
| Earnings Date | Nov 5, 2026 |
About DYN
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incor... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for DYN stock is "Strong Buy." The 12-month stock price target is $34.33, which is an increase of 89.98% from the latest price.
News
Dyne Therapeutics reports Q3 EPS ($1.06), consensus (88c)
Reports Q3 research and development expenses $161.7M vs. $97.2M last year. Reports Q3 general and administrative expenses $35.3M vs. $16.7M last year. Reports cash, cash equivalents and marketable sec...
Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
- Biologics License Application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 2027 -
Dyne Therapeutics Quarterly report: Q3 2026
Dyne Therapeutics has published its Q3 2026 quarterly earnings report on November 5, 2026.
Dyne Therapeutics Earnings release: Q3 2026
Dyne Therapeutics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Oppenheimer downgrades Dyne Therapeutics as vHOT uncertainty reduces confidence
As previously reported, Oppenheimer downgraded Dyne Therapeutics (DYN) to Perform from Outperform with a price target of $15, down from $40. Although the firm views Dyne’s DM1 therapy as superior…
Dyne Therapeutics downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Dyne Therapeutics (DYN) to Perform from Outperform with a price target of $15, down from $40.
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...
Dyne Therapeutics price target lowered to $32 from $50 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Dyne Therapeutics (DYN) to $32 from $50 and keeps a Buy rating on the shares. The company’s update yesterday update supports the…
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a ma...
Piper confident Dyne’s Zeleciment rostudirsen will win January FDA approval
Piper Sandler is confident Dyne Therapeutics’ (DYN) Zeleciment rostudirsen will gain accelerated approval in Duchenne muscular dystrophy boys amenable to exon 51 skipping by the January 21st PDUFA dat...
Dyne Therapeutics management to meet with Piper Sandler
Meeting to be held on October 5-8 hosted by Piper Sandler.
Dyne Therapeutics Transcript: 2026 Global Healthcare Conference
The conference highlighted a differentiated genetic medicine platform with strong clinical data in DMD and DM1, including functional improvements and high dystrophin levels. Key catalysts include an upcoming product approval, pivotal data readouts, and pipeline expansion, with a robust financial runway.
Dyne Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Key neuromuscular medicines are set for launch, with strong clinical data in DM1 and DMD programs. The company is leveraging its FORCE platform for efficient scaling, has robust launch preparations, and holds $1.3B in cash to support multiple product launches and pipeline expansion.
Dyne Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Transitioning to commercial stage with two major drugs, the company leverages its FORCE platform for differentiated delivery and robust clinical progress. Key programs in DM1 and DMD show strong efficacy and regulatory momentum, with a broad pipeline and $1.3B cash runway supporting growth.
Dyne Therapeutics price target lowered to $36 from $45 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Dyne Therapeutics (DYN) to $36 from $45 and keeps an Overweight rating on the shares. The analyst says Novartis’ (NVS) Phase 3…
Dyne Therapeutics price target lowered to $30 from $35 at RBC Capital
RBC Capital lowered the firm’s price target on Dyne Therapeutics (DYN) to $30 from $35 and keeps an Outperform rating on the shares. The firm’s thesis remains intact despite Novartis’…
Dyne Therapeutics price target lowered to $26 from $30 at Baird
Baird analyst Brian Skorney lowered the firm’s price target on Dyne Therapeutics (DYN) to $26 from $30 and keeps an Outperform rating on the shares. The firm updated its model…
Dyne Therapeutics downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Tessa Romero downgraded Dyne Therapeutics (DYN) to Underweight from Neutral with a price target of $10, down from $17. The firm believes Novartis’ (NVS) Phase 3 trial miss…
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis' treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns about the prospects of similar therapie...
Dyne Therapeutics falls -15.4%
Dyne Therapeutics (DYN) is down -15.4%, or -$3.74 to $20.54.
Dyne Therapeutics falls -22.3%
Dyne Therapeutics (DYN) is down -22.3%, or -$5.41 to $18.88.
Dyne Therapeutics should be bought on weakness, says Stifel
Stifel says Dyne Therapeutics (DYN) shares will be under pressure after Novartis (NVS) announced that del-desiran failed its Phase 3 trial for myotonic dystrophy type 1. Investors had mostly viewed…
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings
- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose portion of the trial to be compared against a matched natural history cohort -
Dyne ‘claims frontrunner status in DM1’ after Novartis failure, says Jefferies
Jefferies Novartis’ (NVS) Phase 3 HARBOR study failure with del-desiran in DM1 may negatively impact the space, but thinks Dyne Therapeutics’ (DYN) zbasivarsen still has a chance to succeed and…
Dyne Therapeutics sinks after Novartis myotonic dystrophy miss
Shares of Dyne Therapeutics (DYN) are moving lower after Novartis (NVS) said its Phase III study evaluating del-desiran in people living with myotonic dystrophy type 1 did not demonstrate statisticall...